(¿Â¶óÀÎ) 2020 ´ëÇÑ°©»ó¼±³»ºÐºñ¿Ü°úÇÐȸ Ãß°è½ÉÆ÷Áö¾ö : 2020-12-20±³À°ÀÏÀÚ : 2020-12-20
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ) 2020 ´ëÇÑ°©»ó¼±³»ºÐºñ¿Ü°úÇÐȸ Ãß°è½ÉÆ÷Áö¾ö ÁÖÃÖ±â°ü : ´ëÇÑ°©»ó¼±³»ºÐºñ¿Ü°úÇÐȸ
´ã´çÀÚ : ±èÀº¿µ
¿¬¶ôó : 02-501-2988
À̸ÞÀÏ :
kates1996@naver.com ±³À°Á¾·ù : ¿Ü°ú
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 5 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 80,000¿ø
ºñ°í [»çÀüµî·Ï] Á¤È¸¿ø(Àü¹®ÀÇ):50,000¿ø/ºñȸ¿ø: 60,000¿ø/ÁØȸ¿ø(Àü°øÀÇ ¹× °£È£»ç): 30,000¿ø[ÇöÀåµî·Ï] Á¤È¸¿ø(Àü¹®ÀÇ):70,000¿ø/ºñȸ¿ø: 80,000¿ø/ÁØȸ¿ø(Àü°øÀÇ ¹× °£È£»ç): 50,000¿ø* 65¼¼ÀÌ»ó ¹«·á*º¯°æµÉ¼ö ÀÖÀ½
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 12¿ù 20ÀÏ ÅäÆÄÁîȦ 09:00~09:05 Welcome Remarks ÀÌÀ纹(°í·ÁÀÇ´ë ¿Ü°ú)
±âŸ 12¿ù 20ÀÏ ÅäÆÄÁîȦ 09:05~09:10 ½ÉÆ÷Áö¾ö ÇÁ·Î±×·¥ ¼Ò°³ Á¤ÁøÇâ(°æºÏÀÇ´ë ¿Ü°ú)
±³À°½Ã°£ 12¿ù 20ÀÏ ÅäÆÄÁîȦ 09:10~09:30 Risk stratification of DTC in real world ¼ºÅ¿¬(¿ï»êÀÇ´ë ¿Ü°ú)
±³À°½Ã°£ 12¿ù 20ÀÏ ÅäÆÄÁîȦ 09:30~09:50 Completion thyroidectomy in intermediate-risk DTC ±è¿Ï¿í(°æºÏÀÇ´ë ¿Ü°ú)
±³À°½Ã°£ 12¿ù 20ÀÏ ÅäÆÄÁîȦ 09:50~10:10 TSH suppression and surveillance after lobectomy ¹Ú¿µÁÖ(¼¿ïÀÇ´ë ³»°ú)
±³À°½Ã°£ 12¿ù 20ÀÏ ÅäÆÄÁîȦ 10:10~10:30 Role of RAI ablation in intermediate-risk DTC Á¤½Å¿µ(°æºÏÀÇ´ë ÇÙÀÇÇаú)
ÈÞ½Ä 12¿ù 20ÀÏ 10:30~10:50 Coffee Break ()
±³À°½Ã°£ 12¿ù 20ÀÏ ÅäÆÄÁîȦ 10:50~11:05 Role of external radiotherapy for locally advanced or unresectable thyroid cancer ÀÌÀÍÀç(¿¬¼¼ÀÇ´ë ¹æ»ç¼±Á¾¾çÇаú)
±³À°½Ã°£ 12¿ù 20ÀÏ ÅäÆÄÁîȦ 11:05~11:20 Targeted therapy for persistent thyroid cancer ½Åµ¿¿±(¿¬¼¼ÀÇ´ë ³»°ú)
±³À°½Ã°£ 12¿ù 20ÀÏ ÅäÆÄÁîȦ 11:20~11:35 Radio-frequency ablation for recurrent thyroid cancer in high-risk surgical patients ÃÖ¿µÁØ(¿ï»êÀÇ´ë ¿µ»óÀÇÇаú)
±³À°½Ã°£ 12¿ù 20ÀÏ ÅäÆÄÁîȦ 11:35~12:10 Case-based open discussion: Anaplastic de-differentiation ±è¼®¸ð(¿¬¼¼ÀÇ´ë ¿Ü°ú)
½Ä»ç 12¿ù 20ÀÏ 12:10~13:00 Lunch ()
±³À°½Ã°£ 12¿ù 20ÀÏ ÅäÆÄÁîȦ 13:00~13:20 Multiple Endocrine Neoplasia Type I ±èÁ¤Èñ(¼¿ïÀÇ´ë ³»°ú)
±³À°½Ã°£ 12¿ù 20ÀÏ ÅäÆÄÁîȦ 13:20~13:40 Multiple Endocrine Neoplasia Type II À¯Çü¿ø(¼¿ïÀÇ´ë ¿Ü°ú)
±³À°½Ã°£ 12¿ù 20ÀÏ ÅäÆÄÁîȦ 13:40~14:00 Treatment for family member of MEN I/II ¾ÈÈ¿µ(Áß¾ÓÀÇ´ë ³»°ú)
±³À°½Ã°£ 12¿ù 20ÀÏ ÅäÆÄÁîȦ 14:00~14:20 Familiar non-medullary thyroid cancer ÀÓ½ÂÅÃ(°¡Å縯ÀÇ´ë ¿Ü°ú)
ÈÞ½Ä 12¿ù 20ÀÏ 14:20~14:40 Coffee Break ()
±³À°½Ã°£ 12¿ù 20ÀÏ ÅäÆÄÁîȦ 14:40~15:00 Work up and localization for primary hyperparathyroidism ÀÌÁØÇù(°¡ÃµÀÇ´ë ¿Ü°ú)
±³À°½Ã°£ 12¿ù 20ÀÏ ÅäÆÄÁîȦ 15:00~15:20 Surgical approach to hyperparathyroidism Á¤Á¾ÁÖ(¿¬¼¼ÀÇ´ë ¿Ü°ú)
±³À°½Ã°£ 12¿ù 20ÀÏ ÅäÆÄÁîȦ 15:20~15:40 Management of persistent/recurrent hyperparathyroidism after surgery °È£Ã¶(Àü³²ÀÇ´ë ³»°ú)
±³À°½Ã°£ 12¿ù 20ÀÏ ÅäÆÄÁîȦ 15:40~16:00 Management of postoperative hypoparathyroidism ÀÌ°æ¾Ö(ÀüºÏÀÇ´ë ³»°ú)